Apricus Biosciences Announces Corporate Goals for 2013

Published: Jan 03, 2013

SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) today announced its corporate goals for 2013, which includes focusing its corporate strategy on its high value assets such as Vitaros® for erectile dysfunction ("ED") and Femprox® for female sexual arousal disorder ("FSAD") and plans to seek a buyer for its oncology supportive care products, which consists of two approved products now sold in the United States. The planned divestiture will allow Apricus Bio to better align its resources with its main corporate objectives.

Back to news